Anorexia News and Research

RSS

Online Negative Enabling Support Group embraces anorexia as a choice

It can be a helpless and heartbreaking situation for families as they try to confront a family member with an eating disorder. What they may not know is that there's a society on the Internet that is dedicated to thwarting any recovery from this dangerous and possibly fatal behavior.

23 Feb 2011

Study: Women with anorexia draw themselves with prominently different characteristics

Women suffering from anorexia or bulimia draw themselves with prominently different characteristics than women who do not have eating disorders and who are considered of normal weight. This has been revealed in a new joint study from the University of Haifa, Soroka University Medical Center and Achva Academic College, Israel, published in The Arts in Psychotherapy.

14 Feb 2011

Urocortin system plays central role in regulating stress responses

Post-traumatic stress disorder can affect soldiers after combat or ordinary people who have undergone harrowing experiences. Of course, feelings of anxiety are normal and even desirable - they are part of what helps us survive in a world of real threats. But no less crucial is the return to normal - the slowing of the heartbeat and relaxation of tension - after the threat has passed.

9 Feb 2011

Study reveals Facebook users may face risk of developing eating disorders

The same has been found with regard to exposure to music and fashion on the Internet, and to harmful programs on TV. The study also reveals that the risk of developing eating disorders in adolescent girls is moderated when there is more parental supervision over viewing habits.

8 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

GSA commends '2010 Dietary Guidelines for Americans'

The Gerontological Society of America (GSA) - the nation's largest interdisciplinary organization devoted to the field of aging - commends the federal government's recent release of the "2010 Dietary Guidelines for Americans" and particularly applauds its inclusion of specific advice for older adults.

4 Feb 2011

Baxter launches OLIMEL emulsion for parenteral nutrition

Baxter International today announced the launch of OLIMEL emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's Clinical Nutrition Week.

From Baxter International Inc. 31 Jan 2011

Way of experiencing internal state of body influences perception of body from the outside

A new study, led by Dr Manos Tsakiris from Royal Holloway, University of London, suggests that the way we experience the internal state of our body may also influence how we perceive our body from the outside, as for example in the mirror. The research appears today (5 January) in the Proceedings of the Royal Society B.

5 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.

6 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

Eating Disorder Hope partners with MyPyramid to help eating disorder sufferers

Eating Disorder Hope, a respected independent resource for sufferers of anorexia, bulimia and overeating disorders, has partnered with MyPyramid to help eating disorder sufferers find nutritional and healthy lifestyle support.

24 Nov 2010

Scientists identify gene variants associated with eating disorder

Scientists at The Children's Hospital of Philadelphia have identified both common and rare gene variants associated with the eating disorder anorexia nervosa.

20 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

Anorexia News and Research

Online Negative Enabling Support Group embraces anorexia as a choice

Study: Women with anorexia draw themselves with prominently different characteristics

Urocortin system plays central role in regulating stress responses

Study reveals Facebook users may face risk of developing eating disorders

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

GSA commends '2010 Dietary Guidelines for Americans'

Baxter launches OLIMEL emulsion for parenteral nutrition

Way of experiencing internal state of body influences perception of body from the outside

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Eating Disorder Hope partners with MyPyramid to help eating disorder sufferers

Scientists identify gene variants associated with eating disorder

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News